Navigation Links
Helix BioPharma Corp. announces management changes
Date:11/15/2007

AURORA, ON, Nov. 15 /PRNewswire-FirstCall/ - Helix BioPharma Corp. (TSX, FSE: "HBP") today announced position changes for Dr. Donald Segal and John Docherty. Effective immediately, the joint role of Chief Executive Officer and President formerly held by Dr. Segal will be separated whereby Dr. Segal will remain the Company's Chief Executive Officer and Mr. Docherty will assume the role of President.

"These changes are being made as we strive to expand our corporate initiatives, primarily in the U.S.A.," said Dr. Segal. "Moving forward, I am pleased to have John take on added responsibilities so that I may increasingly focus my time on growing our business by developing new financial, partnering and other strategic initiatives for the Company. John will concentrate on enhancing our public profile, overseeing our advancing clinical programs and managing our related day to day operations."

Dr. Segal and Mr. Docherty have a history of proven leadership with the Company. Dr. Segal is a founding partner, serves on the board of directors and had been Chief Executive Officer and President since 2004. Mr. Docherty joined the Company in 1999 with degrees in toxicology and pharmacology and a comprehensive background in pharmaceutical product and corporate development. At Helix, Mr. Docherty has been instrumental in developing the Company's lead product candidate, Topical Interferon Alpha-2b, in addition to supporting the Company's growing investor and media relations initiatives. Previously, Mr. Docherty served as Vice President, Corporate Development since 2002.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP".

The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements and information regarding Helix's strategic, financing and product development initiatives. Forward-looking statements and information can be identified by the use of forward-looking terminology such as "will", "strive to expand", "enhancing", "advancing", "growing", "developing" and "initiatives". Helix's actual results could differ materially from those anticipated in these forward-looking statements and information as a result of numerous risks, uncertainties and assumptions, including without limitation, Helix's need for additional capital in the near term and in future, which may not be available on acceptable terms or at all; uncertainty whether Helix's strategic and financing initiatives in the U.S.A. will be successful; and uncertainty whether Topical Interferon Alpha-2b, L-DOS47, or any other product will be developed and marketed successfully as a drug or at all. See a description of other risks and uncertainties affecting Helix and its business, as contained in Helix's latest Annual Information Form and other filings with the Canadian Securities Regulatory Authorities at http://www.sedar.com, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements and information are based on the assumptions, beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation, except as required by law, to update any forward-looking statement or information should those assumptions, beliefs, opinions or expectations, or other circumstances change.


'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
9. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 Oxford Gene Technology ... NGS panel range with the launch of the SureSeq myPanel™ ... of variants in familial hypercholesterolemia (FH). The panel delivers single ... a single small panel and allows customisation by ,mix and ... exons for LDLR , P C ...
(Date:12/8/2016)... Worcester, Mass (PRWEB) , ... December 08, 2016 ... ... KbioBox genetic data bioInformatics portal. In response to client demand KbioBox developed a ... gene edit biodesign program. Both are accessible from KBioBox’s new website, https://www.kbiobox.com/ ...
(Date:12/8/2016)... Francisco, CA (PRWEB) , ... December 08, 2016 ... ... Oculus as finalists in the World Technology Awards. uBiome is one of just ... received across all categories. , In addition to uBiome, companies nominated as finalists ...
(Date:12/8/2016)... , Dec. 8, 2016  Soligenix, Inc. (OTCQB: ... company focused on developing and commercializing products to ... medical need, announced today the long-term follow-up data ... (dusquetide), a first-in-class Innate Defense Regulator (IDR), in ... and neck cancer patients undergoing chemoradiation therapy (CRT).  ...
Breaking Biology Technology:
(Date:11/30/2016)... , Nov. 30, 2016 Not many of us realize that we ... of recovery so we need to do it well. Inadequate sleep levels have been ... blood pressure, stroke, diabetes, and even cancer. Maybe now is the best ... that could help them to manage their sleep quality? ... ...
(Date:11/29/2016)... BOSTON , Nov. 29, 2016 BioDirection, ... rapid point-of-care products for the objective detection of concussion ... the company has successfully completed a meeting with the ... company,s Tbit™ blood test Pre-Submission Package. During the meeting ... Tbit™ system as a precursor to commencement of a ...
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
Breaking Biology News(10 mins):